Novartis readies reps for new launches

Share this article:
Novartis is boosting its sales force size ahead of anticipated drug launches, the industry trade group, the National Association of Pharmaceutical Sales Representatives (NAPSR) said.

The drugmaker penned a recruitment ad agreement with NAPSR, as the company looks to fill “nearly a thousand sales positions,” according to a release.

Calls to Novartis to obtain further details of the agreement went unreturned at press time.

Novartis is anticipating the approval of Galvus (type 2 diabetes) and Exforge (for hypertension) before the end of 2007's first quarter, chief marketing officer Kurt Graves said during UBS' Global Life Sciences conference in September.

“What we don't want to tell you is how we have set up our field force,” he said. “Every pharma company needs to come up with innovative go-to market strategies,” to be successful.

Nancy Lurker, SVP, chief marketing officer, said Novartis' efforts will undergo changes in light of these launches.  

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...